Chlorpromazine versus atypical antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Saha, Kumar B ^a   Sampson, Stephanie ^b   Zaman, Rashid U ^c  

^a SEACROFT HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Oxford Policy Management   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907277709     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010631     Document Type: Article

References (58)

1. Adams C, Rathbone J, Thornley B, Clarke M, Borrill J, Kristian W, Awad AG. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine - http://www.biomedcentral.com/1741-7015/3/15 2005;3(15):1-7. [DOI: ]
2. Adams CE, Tharyan P, Coutinho ES, Stroup TS. The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry: the journal of mental science 2006; Vol. 189:391-2. [PUBMED: 17077426]
3. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: ]
4. Ahmed U, Jones H, Adams Clive E. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: ;: CD007445]
5. Almerie MQ, Alkhateeb H, Essali A, Matar Hosam E, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: ;: CD006329]
6. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
7. Arana G W. An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry 2000;61(Suppl 8):5-11.
8. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al.The effect of atypical antipsychotic drugs, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008;32(1):42-8.
9. Bland R C, Parker J H, Orn H. Prognosis in schizophrenia, prognostic predictors and outcome. Archives of General Psychiatry 1978;35(1):72-7. [DOI: ]
10. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
11. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
12. Caccia S, Pasina L, Nobili A. New atypical antipsychotic drugs for schizophrenia: iloperidone. Drug Design, Development and Therapy 2010;4:33-48.
13. Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatric Disease and Treatment 2010;7:429-41.
14. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
15. Delay J, Deniker P. The treatment of psychosis in a derivative of the neuroleptic hibernotherapie method [google translate] [Le traitement des psychoses par une methode neuroleptique derivee de l'hibernotherapie]. In: Ossa PC editor(s). CR Congres des Medicins Alienistes et Neurologistes de France. Paris: Masson, 1952:479.
16. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
17. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington DC: American Psychiatric Association, 2000.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
21. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
22. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
23. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
25. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Hutton Jane L. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
27. World Health Organization. F-20. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: Divison of Mental Health, WHO, 1992:86-109.
28. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. JPET 1988;244(2):685-93.
29. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
30. Kinon B J, Lieberman J A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124(1-2):2-34. [DOI: ]
31. Kraeplin E. Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone, 1919.
32. Laborit H, Huguenard P. Artificial hibernation by physical and pharmacodynamic means [Google translate] [L'Hibernation artificielle par Moyens pharmacodynamiques et physiques]. Presse Medicale 1951;59:1329.
33. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
34. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
35. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
36. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua Wan Lian LC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: ;: CD004278]
37. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
38. Liu X, De HS. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: ;: CD007778]
39. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
40. Mathews M, Muzina D. Atypical antipsychotics: New drugs, new challenges. Cleveland Clinic Journal of Medicine 2007;74(8):597-606.
41. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30:67-76. [DOI: ]
42. Meltzer H Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18-27. [DOI: ]
43. Nadal R. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Reviews 2001;7(3):265-82.
44. Odejide AO, Ban TA. Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. International Pharmacopsychiatry 1982;17:163-9.
45. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
46. Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Annals of Pharmacotherapy 2012;46(7-8):1033-46.
47. Rzewuska M. Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature. Psychiatria Polska 1998 Sep-Oct;32(5):655-66. [PUBMED: 9921002]
48. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005;2(5):e141. [DOI: ]
49. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
50. Smith TLL, Carter CW. Asenapine: a novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. Journal of Pharmacy Technology 2010;26:352-61.
51. Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology 1999;39(2):81-5.
52. Toren P, Samuel E, Weizman R, Golomb A, Eldar S, Laor N. Emergence of transient compulsive symptoms during treatment with clothiapine. Journal of the American Academy of Child & Adolescent Psychiatry 1995;34(11):1469-72. [DOI: ]
53. Turner T. Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.) 2007;334 Suppl 1:s7. [PUBMED: 17204765]
54. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
55. World Health Organization. WHO model list of essential medicines. WHO Essential Medicines List - http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf March 2011; Vol. 17th edition:30.
56. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
57. Yorston G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatric Bulletin 2000;24:130-2.
58. Zhang W, Bymaster FPP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999;141(3):267-78. [DOI: ]